United States Patent 4,879,277: Scope, Claims, Expiration, and Zalcitabine Patent Landscape

U.S. Patent 4,879,277 covers methods of treating HIV and other retroviral infections with 2',3'-dideoxycytidine, also known as zalcitabine or ddC. Its claims extend to ddC salts and esters, selected dosage ranges, oral and parenteral administration, intracellular triphosphate delivery, and liposomal formulations. The patent issued on November 7, 1989, and its 17-year term expired on November 7, 2006. It therefore creates no current U.S. patent barrier to generic zalcitabine development. [1]

The patent was historically important because it claimed therapeutic use of ddC before zalcitabine was approved as Hivid. Its commercial value has ended because zalcitabine is no longer a significant marketed antiretroviral, the patent has expired, and modern HIV treatment uses combination regimens based on newer agents.

What does U.S. Patent 4,879,277 protect?

The patent protects treatment methods using 2',3'-dideoxycytidine in a pharmaceutically acceptable carrier. The claims are method-of-treatment claims rather than claims to a novel chemical compound, a specific pharmaceutical composition, or a manufacturing process.

Patent element	Coverage under U.S. 4,879,277
Active ingredient	2',3'-dideoxycytidine, or ddC
Drug identity	Zalcitabine
Chemical variants	Salts and esters
Primary disease	HIV infection
Broader disease category	Retroviral disease
Therapeutic objective	Treatment or alleviation of cytopathic destructive effects
Dosage	0.03-0.5 mg/kg, four to 12 times daily in claim 9
Administration routes	Oral, intravenous, rectal, nasal, and vaginal
Intravenous dosing	About 0.03-0.25 mg/kg
Oral dosing	About 0.06-0.5 mg/kg
Delivery systems	Normal saline, liposomes, intracellular carriers
Special formulation	Orange juice with sodium chloride
Legal status	Expired

The independent claims are claims 1, 7, and 17. Claims 1 and 7 are the principal broad claims. Claim 17 is a separate independent claim directed to ddC in a liposome carrier.

How broad are the independent claims?

Claim 1: HIV treatment using ddC

Claim 1 requires four core elements:

A patient infected with HIV.
Administration to that patient.
An effective amount.
A composition containing ddC, a salt, or an ester in a pharmaceutically acceptable carrier.

The claim does not require a particular dose, route, formulation, treatment duration, viral-load threshold, CD4 count, or clinical endpoint. The phrase “effective amount” is functional and generally requires proof that the administered amount was capable of producing the claimed therapeutic result.

Claim 1 is broad in subject matter but limited to HIV. It potentially covers oral tablets, capsules, solutions, injections, and other formulations if they contain ddC or a covered derivative in a pharmaceutically acceptable carrier.

The claim does not require ddC to be the only active ingredient. A composition containing ddC together with other antiretrovirals would generally fall within the “comprising” language if the remaining limitations were met.

Claim 7: Retroviral disease treatment

Claim 7 expands the disease limitation from HIV to any retroviral disease. It requires:

A patient infected with a retrovirus.
An antiviral composition.
A viral-suppressing effective amount.
ddC in a pharmaceutically acceptable carrier.
Alleviation of cytopathic destructive effects.

This claim is broader in disease scope than claim 1 but introduces potentially more demanding functional language. The accused treatment must be directed to a retroviral infection and must provide viral suppression or alleviate the specified cytopathic effects.

Claim 7 could theoretically reach retroviruses other than HIV, but its practical commercial importance was tied to HIV therapy. The patent’s specification and historical development were associated primarily with HIV and AIDS research.

Claim 17: Liposomal ddC

Claim 17 covers a method of treating retroviral disease using ddC in a liposome carrier. It is independent and does not depend on claim 7, even though it repeats much of claim 7’s therapeutic concept.

The claim has a narrower formulation limitation than claim 7. A conventional oral or injectable ddC formulation without liposomes would not satisfy claim 17 solely because it contains ddC. Conversely, a liposomal ddC product could fall within claim 17 even if it did not use one of the specific dosage ranges in claims 9, 15, or 16.

What do the dependent claims add?

Claim	Additional limitation	Scope effect
2	ddC in triphosphate form; carrier suitable for intracellular administration	Narrows the active form and delivery objective
3	Normal saline carrier	Covers a specific injectable carrier
4	Triphosphate contained in a liposome	Combines intracellular triphosphate and liposomal delivery
5	Phosphorylated ddC in a liposome	Broader than claim 4 regarding phosphorylation level
6	Phosphorylated ddC is a triphosphate	Narrows claim 5 to the triphosphate
8	Retrovirus is HIV	Narrows claim 7 to HIV
9	0.03-0.5 mg/kg, four to 12 times daily	Adds dose and frequency limitations
10	Oral administration	Covers oral delivery
11	Intravenous administration	Covers IV delivery
12	Continuous IV infusion	Narrows claim 11
13	Rectal, nasal, or vaginal administration	Covers specified mucosal routes
14	ddC in orange juice with sodium chloride	Covers a particular administration vehicle
15	IV administration at about 0.03-0.25 mg/kg	Specific parenteral dose range
16	Oral administration at about 0.06-0.5 mg/kg	Specific oral dose range

Claims 2 through 6 are technically unusual because the claims move from ddC as a nucleoside to phosphorylated ddC, including the active triphosphate. Nucleoside triphosphates are highly polar and generally have poor passive cellular penetration. The liposome limitations address intracellular delivery by encapsulating the phosphorylated compound.

What pharmaceutical formulations are protected?

The patent covers several formulation concepts, but only as part of a treatment method.

Conventional pharmaceutical carriers

Claims 1 and 7 encompass ddC in a pharmaceutically acceptable carrier. The carrier language is broad and could include:

Aqueous solutions
Saline
Oral liquids
Tablets and capsules
Injectable formulations
Excipients used in solid dosage forms
Delivery vehicles for mucosal administration

Claim 3 specifically identifies normal saline. The claim does not require a particular saline concentration or injection volume.

Liposomal formulations

Claims 4, 5, 6, and 17 cover liposomal delivery. The relevant claims distinguish between:

ddC triphosphate in a liposome;
phosphorylated ddC in a liposome; and
ddC in a liposome carrier.

The liposome claims do not appear to require a particular lipid composition, particle size, lamellarity, encapsulation efficiency, release profile, or targeting ligand. That creates potentially broad claim language, but the practical enforceability of broad liposome claims would depend on the patent specification’s written description and enablement support.

Orange juice and sodium chloride

Claim 14 covers administration of ddC in orange juice with sodium chloride. This is a narrow method claim. It is commercially significant only if a product uses that exact administration approach or an equivalent formulation that meets the claim’s limitations.

The claim does not appear to require a specific orange juice brand, sodium chloride concentration, pH, dosage volume, or dosing schedule. Those omissions make the claim potentially broad within its narrow formulation category.

When did U.S. Patent 4,879,277 expire?

U.S. Patent 4,879,277 issued on November 7, 1989. Because it was governed by the pre-Uruguay Round patent term regime, its ordinary term was 17 years from issue. The expected expiration date was November 7, 2006. [1]

Event	Date
Patent issued	November 7, 1989
Statutory term	17 years from issue
Expected expiration	November 7, 2006
Current status	Expired
Current exclusivity value	None

The patent cannot support a present-day infringement action based on administration, sale, or manufacture of ddC in the United States. It also cannot support a current Paragraph IV certification alleging that a proposed generic product would infringe an unexpired patent.

What was the FDA and Orange Book status of zalcitabine?

Zalcitabine was approved by the FDA as Hivid for HIV infection in 1992. The product was associated with Hoffmann-La Roche and was supplied as an oral antiretroviral. [2]

Zalcitabine was an early nucleoside reverse transcriptase inhibitor. Its use declined because of toxicity concerns, including peripheral neuropathy and pancreatitis, and because later combination therapies offered better efficacy, tolerability, and dosing convenience. The product was ultimately discontinued from routine commercial use. [2][3]

Regulatory issue	Status
Active ingredient	Zalcitabine, ddC
FDA product	Hivid
Dosage form	Oral tablets
FDA approval period	Approved in 1992
Current clinical role	No established role in contemporary standard HIV therapy
Orange Book patent barrier	No current enforceable barrier from U.S. 4,879,277
Biosimilar pathway	Not applicable
Generic pathway	Small-molecule ANDA pathway, subject to current FDA reference-product requirements

The Orange Book distinguishes drug-product approval status from patent enforceability. Even if Hivid or a historical product listing remains in an archived Orange Book edition, an expired patent cannot delay approval under the Hatch-Waxman framework. [4]

Are there Paragraph IV challenges to U.S. Patent 4,879,277?

No current Paragraph IV risk exists for U.S. Patent 4,879,277 because the patent expired in 2006. A Paragraph IV certification is relevant only to a listed patent that remains unexpired or otherwise carries legal significance for the proposed drug application.

Historically, a generic zalcitabine applicant could have addressed the patent through:

Paragraph IV certification;
a statement that the patent had expired;
a Paragraph III certification with approval effective after expiration; or
a determination that the patent was not relevant to the proposed product.

The patent’s broad treatment claims could have raised certification issues for an ANDA directed to zalcitabine, especially if the Orange Book listed the patent against Hivid. Those issues are now historical because the patent term ended almost two decades ago.

Which companies challenged or licensed the patent?

The supplied record does not establish a confirmed list of Paragraph IV filers, patent settlements, or license agreements involving U.S. Patent 4,879,277. The patent was associated with government-sponsored HIV research and preceded the commercial Hivid product. The patent record alone does not prove that a particular generic company challenged it or that a licensing transaction occurred.

No current license is needed to practice the expired patent in the United States. A license could still be relevant to separate rights, including:

unexpired formulation patents;
manufacturing patents;
foreign patents;
know-how;
trademarks;
regulatory data;
contractual restrictions; or
third-party liposome technology.

Those rights are distinct from U.S. Patent 4,879,277.

How strong was the patent estate?

The patent was commercially meaningful during the early development of zalcitabine but is weak as a current exclusivity asset.

Strength factor	Assessment
Chemical compound coverage	Limited; the claims are method claims, not broad compound claims
HIV treatment coverage	Broad in claim 1, but expired
Retroviral coverage	Broad in claim 7, subject to functional proof
Dosage coverage	Narrower claims with defined ranges
Formulation coverage	Specific carrier and liposome claims
Manufacturing protection	None apparent from the supplied claims
Current enforceability	None
Biosimilar relevance	None
Generic blocking value	None
Historical value	High for early ddC/HIV development

The principal weakness was dependence on treatment use. A method patent does not prevent independent manufacture of the active ingredient unless the manufacturing conduct also falls within another enforceable claim. It also does not provide the same product-level control as a composition-of-matter patent.

The patent was stronger against a product expressly labeled or promoted for HIV treatment during its term. It was weaker against off-label use, non-HIV retroviral applications, or products whose use could not be linked to the claimed therapeutic method, depending on the evidence and applicable induced-infringement standards.

What generic entry risks exist?

Current generic entry risk from this patent is zero because the patent has expired. The commercial risk assessment for a modern zalcitabine product would instead focus on regulatory and market barriers.

Patent risk

No live U.S. rights arise from the supplied claims. A new entrant would need to investigate later patents covering:

salt selection;
polymorphs;
particle size;
sustained release;
combination products;
liposomal systems;
manufacturing improvements;
analytical methods; and
foreign-market rights.

Regulatory risk

Zalcitabine is an old small molecule, so the relevant pathway would generally be an ANDA if an appropriate reference product and regulatory basis were available. No biosimilar application would be appropriate because zalcitabine is not a biologic. [4]

Commercial risk

The main barriers are likely to be market demand, clinical obsolescence, safety concerns, supply economics, and the absence of a strong treatment position in current HIV guidelines. The absence of patent protection does not create a commercially attractive market by itself.

How does the patent compare with modern HIV drug estates?

U.S. Patent 4,879,277 is narrower in technology and weaker in lifecycle control than modern HIV patent estates.

Estate type	Typical protection	Comparison with U.S. 4,879,277
Nucleoside analog composition patent	Active ingredient and salts	4,879,277 does not primarily claim the compound itself
Product formulation patent	Tablet, capsule, long-acting or controlled-release product	4,879,277 has limited carrier and liposome method claims
Combination patent	Fixed-dose HIV regimen	4,879,277 does not claim a modern combination regimen
Method-of-use patent	Treatment of a defined patient population	4,879,277 broadly claims HIV and retroviral treatment
Manufacturing patent	Process, intermediate, purification, crystallization	No manufacturing claims are shown
Biologic estate	Composition, process, formulation, interchangeability	Not relevant to small-molecule ddC
Regulatory exclusivity	NCE, orphan, pediatric, or other FDA exclusivity	Historical only and no longer blocks approval

Modern antiretroviral estates generally combine active-ingredient patents with formulation, combination, manufacturing, and method-of-use claims. The ddC patent is principally a historical therapeutic-use patent.

What is the geographic coverage?

U.S. Patent 4,879,277 has territorial effect only in the United States. It does not establish rights in Europe, Japan, Canada, Australia, or other jurisdictions.

A worldwide freedom-to-operate review would require separate patent-family analysis for:

priority applications;
national-stage filings;
continuation and divisional applications;
foreign grants;
expiry dates;
terminal disclaimers;
supplementary protection certificates; and
local regulatory exclusivity.

The U.S. expiration date cannot be applied automatically to foreign equivalents. For current U.S. development, however, the supplied patent presents no enforceable patent barrier.

Key Takeaways

U.S. Patent 4,879,277 covers therapeutic use of ddC, or zalcitabine, against HIV and other retroviral diseases.
The main independent claims are claims 1, 7, and 17.
Claim 1 covers HIV treatment with ddC, its salts, or esters.
Claim 7 extends to retroviral disease but includes viral-suppression and cytopathic-effect language.
Claim 17 focuses on liposomal ddC.
Dependent claims cover triphosphate delivery, saline, liposomes, oral and IV administration, mucosal routes, dosage ranges, and orange juice with sodium chloride.
The patent issued November 7, 1989, and expired November 7, 2006.
It creates no current U.S. patent or Paragraph IV barrier.
Zalcitabine is a small molecule, so biosimilar analysis is irrelevant.
The principal current risks are regulatory, clinical, manufacturing, and commercial rather than patent-based.
Any new zalcitabine project still requires a separate review of later patents and non-U.S. rights.

FAQs

Is zalcitabine the same drug as 2',3'-dideoxycytidine?

Yes. Zalcitabine is the pharmaceutical name for 2',3'-dideoxycytidine, commonly abbreviated ddC.

Does U.S. Patent 4,879,277 claim the chemical compound zalcitabine itself?

No. The supplied claims principally cover methods of treating HIV or retroviral disease using ddC, its salts, esters, or specified formulations.

Can a company currently sell zalcitabine without a license to this patent?

In the United States, the expired patent does not require a license. Separate unexpired patents, regulatory rights, trademarks, contracts, or foreign rights could create independent restrictions.

Does the patent cover modern combination HIV therapy?

A combination product containing ddC could potentially have implicated the “comprising” language during the patent term, but the patent is expired. It does not claim current antiretroviral combinations as a product class.

Is a liposomal zalcitabine product still protected by claim 17?

No. Claim 17 expired with the patent on November 7, 2006. A later liposomal product would need to be evaluated against other potentially unexpired patents, not this patent.

References

United States Patent and Trademark Office. (1989). U.S. Patent No. 4,879,277: 2',3'-dideoxycytidine as an antiviral agent.
U.S. Food and Drug Administration. (1992). Hivid (zalcitabine) prescribing information. Hoffmann-La Roche.
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0216511	⤷ Start Trial	SPC/GB95/003	United Kingdom	⤷ Start Trial
European Patent Office	0216511	⤷ Start Trial	94C0015	Belgium	⤷ Start Trial
Austria	96326	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,879,277

Summary for Patent: 4,879,277